Brief: Reviva Announces Preliminary Topline Data For The Long-Term Open Label Extension Portion Of The Phase 3 Recover Study Evaluating Brilaroxazine In Schizophrenia

Reviva Pharmaceuticals Holdings

16/12/2024 13:37

Dec 16 (Reuters) - Reviva Pharmaceuticals Holdings, Inc.
 RVPH.O :
    * REVIVA ANNOUNCES POSITIVE PRELIMINARY TOPLINE DATA FOR THE
LONG-TERM OPEN LABEL EXTENSION PORTION OF THE PHASE 3 RECOVER
STUDY EVALUATING BRILAROXAZINE IN SCHIZOPHRENIA
    * FULL DATA SET FROM OPEN-LABEL EXTENSION (OLE) OF RECOVER
EXPECTED IN Q1 2025
    * ALL THREE DOSES OF BRILAROXAZINE (15 MG, 30 MG AND 50 MG)
TESTED
EFFICACIOUS & GENERALLY WELL-TOLERATED

Source text:  ID:nGNX1Jy68R 
Further company coverage:  RVPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))